PetVivo Holdings, Inc. (OTCQB: PETV”d”) Could make a great Acquisition Target

131

Petco Health and Wellness Company (NASDAQ: WOOF) launched its third IPO in Company history last Thursday, and this time, according to CNN Business, It’s taking aim at fast growing online rivals like Chewy (NASDAQ: CHWY).  

Chewy’s stock has gone parabolic since March trading up 500% and making a new all-time high last Thursday at $115 per share.  

Petco’s shares surged 56% giving the company a market valuation of about $6.2 billion compared to Chewy’s whopping $42.6 billion. If Petco is going to catch up, they are going to need some proprietary assets in their corner, and with biotech in top demand, why not start there. 

August 6, 2019, Petco announced the expansion of its footprint of in-store veterinary hospitals with new regional partners;

Global Veterinary Partners (GVP), based out of Weston;

Florida; VitalPet, based out of Houston, Texas; and 

VetnCare, based out of Oakland, California

In addition to these new partnerships, Petco is expanding operations with existing partners Thrive Affordable Vet Care and The Pet Vet (which have partnered with Petco since 2017 and 2009, respectively) to open the more than 50 veterinary hospitals currently operating within Petco stores in Texas, California, Colorado, North Carolina, South Carolina, Florida, Utah, Oaklahoma, Arkinsas, Kansas and Missouri. 

The new and existing partnerships support and complement Petco’s complete suite of health and wellness services and experiences for pets and pet parents.  But where is its proprietary asset? 

PetVivo Holdings, Inc. (OTCQB: PETVD) (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. 

PetVivo announced in August that the United States Patent and Trademark Office (USPTO) has allowed an important patent related to the Company’s proprietary biomaterial, which the company utilizes to produce its proprietary products. 

PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.

The broad scope of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof,” provides tremendous proprietary protection for a broad range of proprietary products, including the product Kush, a medical device treatment for animal osteoarthritis.

Kush is made from all-natural materials; collagen elastin and heparin, lasts for 12 months or longer and can be repeated each year.  Kush is expected to launch in Q1 2021, with sales in the $4.8 billion dog and horse therapeutics market.  Petvivo (OTCQB: PETV) currently has 16 products in its pipeline, and a portfolio of 19 patents that protect them. 

A company like Petco (NASDAQ: WOOF) who, as CNN Business wrote, is coming for the majors, could benefit from acquiring proprietary technology and PetVivo (OTCQB: PETV) might be a good fit. 

PetVivo (OTCQB: PETVD, PETV), is also on an aggressive growth / valuation path of their own.  The Company published a press release on December 29, 2020 announcing a reverse stock split in efforts to improve the company’s capital structure related to listing requirements for a planned future listing of the company’s common stock on the Nasdaq Capital Market.  

On November 23, 2020, PetVivo Holdings (OTCQB: PETV) filed an 8-K where the Company adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?”  All of which are required by NASDAQ

Audit Committee:

            PetVivo Holdings’ Audit Committee will consist of three or more directors and each committee member will, among other requirements, qualify as an independent director, and at least one of them will qualify as an “audit committee financial expert”, all also as required by NASDAQ Rules. 

Compensation Committee:

            PetVivo Holdings’ Compensation Committee will consist of two or more directors and each committee member will, among other requirements be independent in accordance with the NASDAQ Rules. 

Nominating and Corporate Governance Committee:

            PetVivo Holdings’ Nominating and Corporate Governance Committee will consist of two or more directors and each committee member will qualify as an independent director in accordance with the rules of the NASAQ Stock Market. 

See page 11 of the “Nasdaq Official Listing Guide of June 2020”.

Either path, being acquired by a major, or organically with an up list to a major exchange, PetVivo Holdings, Inc. (OTCQB: PETVD, PETV), is on a track for growth. 

About EmergingGrowth.com

Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated ten thousand three hundred dollars in consideration for its work with PetVivo Holdings, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/68372-7388/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.